Short answer: VA coverage is not automatic. Wegovy is reported as non-formulary in the VA system (SingleCare, December 5, 2025) and requires the VA Criteria for Use plus a non-formulary request; Zepbound is handled the same way in practice, although we could not open the VA formulary tool to confirm its listing as of September 5, 2026. CHAMPVA does not cover GLP-1 drugs when prescribed only for weight loss, although it covers specific products for certain FDA-approved diagnoses. TRICARE has its own prior-authorization rules.
Coverage information was checked September 5, 2026 against the VA CHAMPVA page (updated August 12, 2026), the TRICARE pharmacy FAQ (updated August 6, 2026) and the VA Criteria for Use (April 2026), and can change. This article is educational and is not medical advice.
Start with the right benefit
| Benefit | What the current rule means | Best next step |
|---|---|---|
| VA health care | Coverage can be available when the patient meets the VA Criteria for Use (April 2026: documented lifestyle-intervention participation within the past year plus BMI of 27 or higher with a weight-related comorbidity); Wegovy is reported as non-formulary and needs a non-formulary request. | Ask the VA prescriber which current Criteria for Use applies and whether a non-formulary request was submitted. |
| CHAMPVA | Not covered for weight loss alone. Coverage is diagnosis-specific for listed FDA-approved uses. | Confirm the diagnosis and product against the current CHAMPVA medication notice. |
| TRICARE | Wegovy, Saxenda and Zepbound need prior authorization, and TRICARE's FAQ (August 6, 2026) says beneficiaries pay 100 percent of the cost even when approved; TRICARE For Life and direct-care-only beneficiaries are excluded. | Use the TRICARE formulary tool and have the prescriber submit the required form. |
What CHAMPVA covers
VA states that CHAMPVA does not cover GLP-1 medication prescribed for weight loss. Its current page (updated August 12, 2026) lists Mounjaro, Ozempic, Trulicity, and Victoza for type 2 diabetes; Zepbound for moderate-to-severe obstructive sleep apnea; and Wegovy for MASH or for prevention of major cardiovascular events. Correction, September 2026: an earlier version also listed Rybelsus and a sleep-study recency requirement; neither appears on the current VA page, and both have been removed. Those are diagnosis-based exceptions, not general obesity coverage.
How VA approval usually works
- Discuss eligibility and contraindications with a VA clinician.
- Ask which current VA Criteria for Use document applies to the requested drug.
- Confirm whether required lifestyle treatment, measurements, or comorbidity documentation is in the chart.
- Have the clinician submit the non-formulary request when required.
- If denied, request the exact reason and address the missing criterion or use the available review process.
Do not assume that a retail prescription or another insurer's approval transfers to the VA benefit.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →What to do after a denial
Get the denial reason in writing. A denial may reflect an excluded indication, an unmet clinical criterion, missing documentation, or use of the wrong benefit. Ask the prescriber and pharmacy team whether corrected documentation, a different FDA-approved indication, or an appeal is appropriate. Do not buy an unapproved product marketed as “the same as” an FDA-approved GLP-1 without discussing the safety and legal differences with a clinician.
VA Criteria for Use for Wegovy, April 2026
The VA Pharmacy Benefits Management Services and National Formulary Committee published a revised Criteria for Use for semaglutide (Wegovy) subcutaneous injection and oral tablet for weight management in April 2026. Both inclusion criteria must be met:
- Documented participation in a comprehensive lifestyle intervention covering diet, physical activity and behavioral change, on at least one occasion within the past year; the MOVE! program is one example.
- BMI of 27 kg/m2 or higher with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, prediabetes, dyslipidemia, metabolic syndrome, obstructive sleep apnea, osteoarthritis, metabolic dysfunction-associated steatotic liver disease or heart failure with preserved ejection fraction.
Exclusions include known pregnancy, lactation, type 1 diabetes, a personal or family history of medullary thyroid carcinoma or MEN 2, severe gastrointestinal dysmotility including gastroparesis, a history of pancreatitis unless the cause is known and resolved, and certain diabetic retinopathy findings unless risks and benefits are documented with eye-specialist follow-up. Pregnancy must be excluded before starting in anyone who can become pregnant. The document notes that exceptions are adjudicated locally by each facility's pharmacy and therapeutics committee, so the criteria are a floor, not a guarantee.
TRICARE rules as of August 6, 2026
TRICARE's pharmacy FAQ, last updated August 6, 2026, states that Wegovy, Saxenda and Zepbound are covered for weight management with prior authorization for beneficiaries in TRICARE Prime, Prime Remote, the US Family Health Plan, Select, Young Adult, Reserve Select, Retired Reserve and the Continued Health Care Benefit Program. The FAQ is explicit on cost: "You will pay 100% of the cost for your weight loss drugs even if you have an approved prior authorization." TRICARE For Life beneficiaries and those who receive care only in military facilities are not covered for weight-loss GLP-1s; Military.com (July 29, 2026) dates that exclusion to August 31, 2025 and describes the prior-authorization criteria as a BMI of 30 or higher, or 27 or higher with a comorbidity, plus six months of lifestyle modification and a prior trial of an oral weight-loss medicine. Ozempic, Mounjaro, Trulicity and Victoza remain covered for type 2 diabetes with prior authorization. Correction, September 2026: an earlier version said only that TRICARE may cover these drugs; it omitted the 100 percent cost-share and the plan exclusions.
If coverage is denied: costs and alternatives as of September 5, 2026
- VA copays: for veterans who do get approval, SingleCare (December 5, 2025) reports VA outpatient copays of $0 to $33 per prescription by priority group, with Tier 3 drugs at $11, $22 or $33 for 30-, 60- or 90-day supplies and a $700 annual cap.
- Medicare-eligible veterans: the Medicare GLP-1 Bridge program charges $50 a month for Wegovy, Zepbound KwikPen and Foundayo from July 1, 2026 through December 31, 2027, with prior authorization (healthinsurance.org); TRICARE's own FAQ points Medicare Part D beneficiaries to it.
- Manufacturer self-pay: Wegovy is $199 for each of the first two fills, then $349 a month, with the 7.2 mg pen at $399 and the pill at $149 to $299 (wegovy.com). Zepbound costs $499 a month through the savings program when a commercial plan does not cover it, and $299, $399 or $449 through LillyDirect vials or KwikPens depending on dose, rising to $499 or $699 if a refill is not made within 45 days (Lilly, September 2026). The Wegovy savings card excludes government beneficiaries.
- Compounded semaglutide or tirzepatide: lawful only for a documented individual clinical need now that the FDA shortages are resolved; pharmacy prices vary and are tracked in the Compounded GLP-1 Price Index.
Frequently asked questions
Does the VA cover Wegovy for weight loss?
It may. The April 2026 VA Criteria for Use require documented participation in a comprehensive lifestyle intervention within the past year (MOVE! is one example) and a BMI of 27 or higher with at least one weight-related comorbidity; Wegovy is reported as non-formulary, so a non-formulary request is also needed. Coverage is not automatic.
Does CHAMPVA cover GLP-1 drugs for weight loss?
No. VA states that CHAMPVA does not cover GLP-1 medications prescribed for weight loss alone.
Can CHAMPVA cover Zepbound?
CHAMPVA lists Zepbound coverage for moderate-to-severe obstructive sleep apnea, not for weight loss alone (va.gov, updated August 12, 2026). Documentation requirements for the diagnosis are set through CHAMPVA's prior-authorization process; we could not verify a specific sleep-study recency rule.
Does TRICARE cover weight-loss medication?
TRICARE covers Wegovy, Saxenda and Zepbound for weight management with prior authorization under Prime, Prime Remote, USFHP, Select, Young Adult, Reserve Select, Retired Reserve and CHCBP, but its FAQ (updated August 6, 2026) says you will pay 100 percent of the cost even with an approved prior authorization. TRICARE For Life and direct-care-only beneficiaries are excluded.
What should I do if coverage is denied?
Ask for the exact denial reason, compare it with the current criteria, and work with the prescriber on missing documentation, a review, or an appropriate alternative.
Does the VA cover the Wegovy pill for weight loss?
The April 2026 VA Criteria for Use apply to both the Wegovy subcutaneous injection and the oral tablet for chronic weight management, so the pill is reviewed under the same rules: documented lifestyle-intervention participation within the past year and a BMI of 27 or higher with a weight-related comorbidity, plus a non-formulary request where required. Local VA facilities adjudicate exceptions, so ask your VA prescriber how the request will be submitted.
Can a Medicare-eligible veteran use the GLP-1 Bridge instead?
Yes, if enrolled in Medicare Part D. The Medicare GLP-1 Bridge charges $50 a month for covered anti-obesity GLP-1s, including Wegovy, Zepbound KwikPen and Foundayo, from July 1, 2026 through December 31, 2027, with prior authorization (healthinsurance.org, 2026). TRICARE's August 6, 2026 FAQ refers TRICARE For Life beneficiaries, who cannot get weight-loss GLP-1s through TRICARE, to that program. Compare the $50 copay with VA copays before choosing a path.
What does TRICARE charge for Wegovy or Zepbound?
According to TRICARE's pharmacy FAQ updated August 6, 2026, beneficiaries in covered plans pay 100 percent of the cost of weight-loss drugs even after prior authorization is approved; approval establishes eligibility to fill the prescription through the TRICARE network, not a copay. TRICARE For Life and direct-care-only beneficiaries are excluded. For type 2 diabetes, Ozempic, Mounjaro, Trulicity and Victoza remain covered with prior authorization under normal cost-sharing.
Sources
- VA CHAMPVA notice — diagnosis-specific GLP-1 coverage and weight-loss exclusion.
- VA Formulary Advisor — Wegovy formulary status and prior-approval requirement.
- VA PBM Criteria for Use: Semaglutide (WEGOVY) for Weight Management, April 2026: inclusion and exclusion criteria.
- TRICARE — coverage and prior-authorization overview.
- U.S. Department of Veterans Affairs. CHAMPVA care: GLP-1 medications covered by diagnosis. Last updated August 12, 2026. https://www.va.gov/resources/champva-care/
- VA Pharmacy Benefits Management Services. Criteria for Use: Semaglutide (WEGOVY) Subcutaneous Injection and Oral Tablet for Weight Management. April 2026. https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Semaglutide_WEGOVY_for_weight_management_CFU_Rev_Apr_2026.pdf
- TRICARE. Pharmacy FAQ: Wegovy, Saxenda and Zepbound coverage and cost. Last updated August 6, 2026. https://tricare.mil/FAQs/Pharmacy/PharmProg_Wegovy
- Military.com (Brandon Wile). Ozempic, Wegovy, Mounjaro, Zepbound: what the VA and TRICARE actually cover. July 29, 2026. https://www.military.com/ozempic-wegovy-mounjaro-zepbound-heres-what-the-va-and-tricare-actually-cover
- SingleCare. Does the VA cover Ozempic? (Wegovy formulary status; VA copay tiers). December 5, 2025. https://www.singlecare.com/blog/does-the-va-cover-ozempic/
- healthinsurance.org. Does health insurance cover drugs used for weight loss? (Medicare GLP-1 Bridge, July 1, 2026 to December 31, 2027). 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
- Novo Nordisk. What to pay for Wegovy (self-pay prices; savings card eligibility). Checked September 5, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
- Eli Lilly. Zepbound coverage and savings (savings card and $499 not-covered price). Checked September 5, 2026. https://zepbound.lilly.com/coverage-savings
- Eli Lilly. LillyDirect Zepbound self-pay vial and KwikPen pricing. Checked September 5, 2026. https://www.lilly.com/lillydirect/zepbound
- FormBlends. Compounded GLP-1 Price Index data feed. As of September 3, 2026. https://formblends.com/feeds/glp1-prices.json
Editorial method: FormBlends Editorial Standards Team reviewed official program pages, regulatory material, prescribing information, and primary research where applicable. No clinician or patient review is claimed.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →